Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guérin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic

Louis Lenfant; Thomas Seisen; Yohann Loriot; Morgan Rouprêt

doi:10.1016/j.eururo.2020.04.039

Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guérin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic

Eur Urol. 2020 Jul;78(1):1-3. doi: 10.1016/j.eururo.2020.04.039. Epub 2020 Apr 24.

Authors

Louis Lenfant¹, Thomas Seisen¹, Yohann Loriot², Morgan Rouprêt³

Affiliations

¹ Sorbonne University, GRC 5 Predictive onco-uro, APHP, Urology, Pitié-Salpétrière Hospital, 75013 Paris, France.
² Department of Cancer Medicine, Gustave Roussy Institute, University Paris-Saclay, Villejuif, France.
³ Sorbonne University, GRC 5 Predictive onco-uro, APHP, Urology, Pitié-Salpétrière Hospital, 75013 Paris, France. Electronic address: morgan.roupret@aphp.fr.

Abstract

Non-muscle-invasive bladder cancer patients with COVID-19 are more likely to develop acute respiratory distress syndrome. Thus, several adjustments to the use of intravesical instillations of bacillus Calmette-Guérin should be made during the current pandemic to limit the risk of contamination.

Publication types

Editorial

MeSH terms

Adjuvants, Immunologic / administration & dosage
Administration, Intravesical
Aged
BCG Vaccine / administration & dosage*
Betacoronavirus*
COVID-19
Coronavirus Infections / complications*
Coronavirus Infections / epidemiology
Disease Progression
Drug Administration Schedule
Female
Humans
Male
Neoplasm Invasiveness
Pandemics*
Pneumonia, Viral / complications*
Pneumonia, Viral / epidemiology
SARS-CoV-2
Urinary Bladder Neoplasms / complications
Urinary Bladder Neoplasms / drug therapy*
Urinary Bladder Neoplasms / pathology

Substances

Adjuvants, Immunologic
BCG Vaccine